Author: Ravi Shankar

UAB “Atsinaujinančios energetikos investicijos” (hereinafter, the “Company”) hereby informs that on its initiative of 20 October 2026, the trustee of holders of notes of the Company, ISIN LT0000135840 (hereinafter, the “Notes”), CSC (Sweden) AB (hereinafter, the “Trustee”) has decided to convene the Noteholders’ Meeting, as it is established in item 19 of the Terms and Conditions of the Notes, which will take place on 12 November 2026, at 10:00 (EET, Vilnius time) (hereinafter, the “Meeting”).

The Meeting is being convened because the expected timing of receipt of part of the proceeds from the Company’s ongoing divestment processes does not correspond to the maturity date of the Notes. Therefore, in order to align the redemption date of the Notes with the projected cash flow schedule, the Company proposes to the Meeting that the maturity date of the Notes be extended from 4 December 2026 to 4 December 2027 and to increase the annual interest rate on the Notes to 10 per cent for the extended period from 5 December 2026 to 4 December 2027 (or until their earlier redemption, should the Notes be redeemed before 4 December 2027).

Detailed information regarding the Meeting, the reasons thereof, its venue, possible advance voting in the Meeting, provision of the respective information to the Trustee, proposed draft decisions, their reasoning and regarding other questions is provided in the attached document.

The Company also invites holders of the Notes to participate in remote webinars, taking place on 29 October 2026, during which the management of the Company will present the decisions to be adopted in the Meeting and answer the questions of the Noteholders. Times of the webinars as well as registration links:

• Webinar in Lithuanian: 29 October 2026 10:00 (EET, Vilnius time), https://us06web.zoom.us/webinar/register/WN_Y7sffD8HQO-owuPWVsswtg
• Webinar in English: 29 October 2026 11:00 (EET, Vilnius time), https://us06web.zoom.us/webinar/register/WN_f2VN9ar0QRav6tHJWrOgZw

The Company notes that, as at the date of publication of this notification, the proposed amendments to the terms and conditions of the Notes have not been approved and are subject to the resolutions of the Meeting being convened. Pending their approval (if approved), the existing terms and conditions of the Notes shall remain in force.

Contact person for further information:
Mantas Auruškevičius
Manager of the Investment Company
mantas.auruskevicius@lordslb.lt

Attachment

• Notice regarding Noteholders meeting (AEI decision) (2026 10 20) (EN).pdf

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Oct. 20, 2026 (GLOBE NEWSWIRE) — Entrée Resources Ltd. (TSX:ETG; OTCQB:ERLFF – the “Company” or “Entrée”) is pleased to announce a non-brokered private placement of up to 11,000,000 units of the Company (the “Units”) at a price of C$2.90 per Unit for gross proceeds of up to C$31,900,000 (the “Private Placement”).

Each Unit will consist of one common share and one common share purchase warrant (a “Warrant”) of the Company. Each Warrant entitles the holder to purchase one additional common share of the Company at a price of C$3.95 for a period of three years following the date of issuance. No finder’s fees will be payable in connection with the Private Placement.

Chris Adams, the Company’s President & CEO commented, “Entrée’s Board and management are extremely pleased to announce the Private Placement, a significant component of which is to a new strategic investor, an affiliate of the Tether group of companies. This financing will strengthen our balance sheet as we work to progress the transfer of the Entrée/Oyu Tolgoi joint venture mining licenses to Oyu Tolgoi LLC and engage with the Government Working Group and other Oyu Tolgoi project stakeholders to resolve State ownership in the area of the licenses. A healthy treasury will also afford us the flexibility to conduct a re-evaluation of our corporate strategy, and in particular to investigate the possible merits of growth through the potential addition of value-accretive, synergistic royalties, streams, or other similar interests in high-quality copper and other critical metals projects to complement our world-class asset in Mongolia.”

Closing of the Private Placement is anticipated to occur in the fourth quarter of 2026 and is subject to receipt of all necessary regulatory approvals including acceptance by the Toronto Stock Exchange. The securities issued in connection with the Private Placement will be subject to a hold period of four months plus one day from the date of issuance, in accordance with applicable securities laws. Insiders of the Company may participate in the Private Placement.

The Company has also entered into an agreement with the strategic investor pursuant to which, effective upon closing, the strategic investor will receive participation rights to maintain its pro rata ownership interest in subsequent equity issuances and, if it reaches and maintains an ownership threshold of 15% of the Company’s issued and outstanding common shares, the right to nominate one individual to the Company’s board of directors.   

The net proceeds from the Private Placement are expected to be used for general corporate purposes, including to fund the preparation of the Company’s updated Technical Report in respect of its interest in the Entrée/Oyu Tolgoi joint venture property, increase the Company’s presence in Mongolia, and potentially refund a portion of the deposit and reduce the metal credits the Company is required to deliver under its Equity Participation and Funding Agreement with International Royalty Corporation upon the resolution of all outstanding issues in Mongolia.

The securities being offered pursuant to the Private Placement have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or state securities laws and may not be offered or sold within the United States, or for the account or benefit of persons in the United States or “U.S. Persons”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, absent U.S. federal and state registration or an applicable exemption from the U.S. registration requirements. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States.

ABOUT ENTRÉE RESOURCES LTD.
Entrée Resources Ltd. is a Canadian mining company with a unique carried joint venture interest on a significant portion of one of the world’s largest copper-gold projects – the Oyu Tolgoi project in Mongolia. Entrée has a 20% or 30% carried participating interest in the Entrée/Oyu Tolgoi joint venture, depending on the depth of mineralization. Royal Gold, Inc. (through its wholly owned Canadian subsidiary International Royalty Corporation) and Rio Tinto are major shareholders of Entrée, beneficially holding approximately 24% and 16% of the shares of the Company, respectively. More information about Entrée can be found at www.EntreeResourcesLtd.com.

FURTHER INFORMATION
David Jan
Investor Relations
Entrée Resources Ltd.
Tel: 604-687-4777 | Toll Free: 1-866-368-7330
E-mail: djan@EntreeResourcesLtd.com

This News Release contains forward-looking information within the meaning of applicable Canadian securities laws including, without limitation, with respect to corporate strategies and plans; the potential acquisition and disposition of assets; requirements for additional capital; the proposed Private Placement; anticipated closing of the proposed Private Placement; the ability of the Company to obtain the required regulatory approvals; anticipated use of proceeds; the preparation of an updated Technical Report; the strategic investor’s rights; the Company’s plans to potentially refund a portion of the deposit and reduce the metal credits the Company is required to deliver under its Equity Participation and Funding Agreement with International Royalty Corporation upon the resolution of outstanding issues in Mongolia; and the Company’s efforts and ability to resolve State participation in the area of the Shivee Tolgoi and Javkhlant mining licenses (the “Licenses”) and transfer the Licenses to Oyu Tolgoi LLC.

In certain cases, forward-looking information can be identified by words such as “plans”, “expects” or “does not expect”, “is expected”, “budgeted”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “does not anticipate” or “believes” or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will be taken”, “occur” or “be achieved”. While the Company has based this forward-looking information on its expectations about future events as at the date that such information was prepared, the information is not a guarantee of Entrée’s future performance and is based on numerous assumptions regarding present and future business strategies; the correct interpretation of agreements, laws and regulations; the commencement and conclusion of arbitration proceedings, including the potential benefits, timing and outcome of arbitration proceedings; the Company’s ability to engage in discussions and negotiations with the Government Working Group and the potential timing and outcome of any such discussions; the future ownership of the Licenses; that the Company will continue to have timely access to detailed technical, financial, and operational information about the Entrée/Oyu Tolgoi joint venture property, the Oyu Tolgoi project, and government relations to enable the Company to properly assess, act on, and disclose material risks and opportunities as they arise; local and global economic conditions and the environment in which Entrée will operate in the future, including commodity prices, projected grades, projected dilution, anticipated capital and operating costs, including inflationary pressures thereon resulting in cost escalation, and anticipated future production and cash flows; the anticipated location of certain infrastructure and sequence of mining within and across panel boundaries; the continued ramp-up of the Oyu Tolgoi Lift 1 underground mine; the status of Entrée’s relationship and interaction with the Government of Mongolia, Erdenes Oyu Tolgoi LLC, Oyu Tolgoi LLC, and Rio Tinto; and the Company’s ability to operate sustainably, its community relations, and its social licence to operate.

With respect to the construction and continued development of the Oyu Tolgoi underground mine, important risks, uncertainties and factors which could cause actual results to differ materially from future results expressed or implied by such forward-looking information include, amongst others, an uncertain and unstable global economic and political environment, including China-U.S. tensions and the indirect impacts of the war in Ukraine and conflict in the Middle East, which could lead to critical fuel and other supply shortages, falling commodity prices, trade actions (including increased tariffs, retaliations, and sanctions), and government efforts to exert more control over natural resources or to protect domestic economies by changing contractual, regulatory, or tax measures; the impacts of climate change and the transition to a low-carbon future; the nature of the ongoing relationship and interaction between Oyu Tolgoi LLC, Rio Tinto, Erdenes Oyu Tolgoi LLC and the Government of Mongolia with respect to the continued operation and development of Oyu Tolgoi; applicable taxes and royalty rates; the future ownership of the Licenses; mining operational and development risks, including geotechnical risks and ground conditions; the amount of any future funding gap to complete the Oyu Tolgoi project ramp-up and the availability and amount of potential sources of additional funding; inflationary pressures on prices for critical supplies for Oyu Tolgoi resulting in cost escalation; the ability of Oyu Tolgoi LLC or the Government of Mongolia to deliver a domestic power source for Oyu Tolgoi (or the availability of financing for Oyu Tolgoi LLC or the Government of Mongolia to construct such a source) within the required contractual timeframe; sources of interim power; Oyu Tolgoi LLC’s ability to operate sustainably, its community relations, and its social license to operate in Mongolia; the impact of changes in, changes in interpretation to or changes in enforcement of, laws, regulations and government practises in Mongolia; delays, and the costs which would result from delays, in the ramp-up of the underground mine; the anticipated location of certain infrastructure and sequence of mining within and across panel boundaries; projected commodity prices and their market demand; and production estimates and the anticipated yearly production of copper, gold and silver at the Oyu Tolgoi underground mine.

Other risks, uncertainties and factors which could cause actual results, performance or achievements of the Company to differ materially from future results, performance or achievements expressed or implied by forward-looking information include, amongst others, unanticipated costs, expenses or liabilities; discrepancies between actual and estimated production, mineral reserves and resources and metallurgical recoveries; the impacts of geopolitics on trade and investment; trade tensions between the world’s major economies; development plans for processing resources; matters relating to proposed exploration or expansion; regulatory restrictions (including environmental regulatory restrictions and liability); risks related to international operations, including legal and political risk in Mongolia; risks related to the potential impact of global or national health concerns; risks associated with changes in the attitudes of governments to foreign investment; risks associated with the conduct of joint ventures, including the ability to access detailed technical, financial and operational information; risks related to the Company’s significant shareholders, and whether they will exercise their rights or act in a manner that is consistent with the best interests of the Company and its other shareholders; inability to upgrade Inferred mineral resources to Indicated or Measured mineral resources; inability to convert mineral resources to mineral reserves; conclusions of economic evaluations; fluctuations in commodity prices and demand; changing foreign exchange rates; the speculative nature of mineral exploration; the global economic climate; dilution; share price volatility; activities, actions or assessments by Rio Tinto or Oyu Tolgoi LLC and by government stakeholders or authorities including Erdenes Oyu Tolgoi LLC and the Government of Mongolia; the availability of funding on reasonable terms; the impact of changes in interpretation to or changes in enforcement of laws, regulations and government practices, including laws, regulations and government practices with respect to mining, foreign investment, strategic deposits, royalties and taxation; the terms and timing of obtaining necessary environmental and other government approvals, consents and permits; the availability and cost of necessary items such as water, skilled labour, transportation and appropriate smelting and refining arrangements; unanticipated reclamation expenses; changes to assumptions as to the availability of electrical power, and the power rates used in operating cost estimates and financial analyses; changes to assumptions as to salvage values; ability to maintain the social license to operate; accidents, labour disputes and other risks of the mining industry; global climate change; global conflicts; natural disasters; the impacts of civil unrest; breaches of the Company’s policies, standards and procedures, laws or regulations; increasing societal and investor expectations, in particular with regard to environmental, social and governance considerations; the impacts of technological advancements; title disputes; limitations on insurance coverage; competition; loss of key employees; cyber security incidents; misjudgements in the course of preparing forward-looking information; and those factors discussed in the Company’s most recently filed MD&A and in the Company’s Annual Information Form for the financial year ended December 31, 2025, dated March 5, 2026 filed with the Canadian Securities Administrators and available at www.sedarplus.ca. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The Company is under no obligation to update or alter any forward-looking information except as required under applicable securities laws.

Suncare’s expanding elderly care platform records approximately $3 million in cash collections associated with service-related commissions

YANTAI, China, Oct. 20, 2026 (GLOBE NEWSWIRE) — Decent Holding Inc. (NASDAQ: DXST) (“Decent” or the “Company”) today announced that its senior care business, operated through Suncare (Shanghai) Health Technology Co., Ltd. (“Suncare”), has recorded approximately US$3 million in cash collections associated with service-related commissions since September 2026. The amount is based on the Company’s internal financial records and a reconciliation of relevant bank transaction records for the period.

According to the Company’s internal records, these collections relate to service-related activities conducted through Suncare’s senior care platform. The Company believes these collections represent a meaningful commercial milestone in the development of its senior care business and demonstrate the potential of its expanding service network to generate additional revenue streams.

Building on Previously Reported Financial Performance

For the fiscal year ended October 31, 2025, Decent reported total revenue of approximately US$12.9 million and gross profit of approximately US$3.4 million.

For the six months ended April 30, 2026, the Company’s digital health and wellness business generated approximately US$3.5 million in training revenue, with a gross margin of approximately 75.1%.

Commercial Progress in Senior Care Services

The approximately US$3 million in cash collections associated with service-related commissions since September 2026 reflects commercial activity within Suncare’s senior care operations.

The amounts disclosed represent cash collections based on the Company’s internal financial records and are subject to the Company’s customary financial closing procedures and applicable revenue recognition requirements under U.S. GAAP.

Advancing Commercialization of the Senior Care Platform

Suncare is developing an AI-enabled, community-based senior health and care platform designed to connect older adults with health education, wellness programs, daily-living assistance and other community services.

The Company intends to leverage its expanding network of operating centers, customer relationships and digital platform capabilities to develop multiple revenue streams, including service-related commissions, training, subscriptions and technology-enabled care solutions.

These recent cash collections reflect commercial activity across the Company’s senior care operations and support its strategy of developing service-based business opportunities alongside its continued investment in AI-enabled senior care technologies.

Focus on Sustainable Business Development

Decent believes that the development of service-based business activities supported by actual cash collections represents an important step toward building a more diversified business model.

The Company plans to continue expanding its senior care service offerings while evaluating opportunities to enhance operating efficiency, create recurring revenue and strengthen long-term financial performance.

About Decent Holding Inc.

Decent Holding Inc. (NASDAQ: DXST) specializes in the provision of wastewater treatment by cleansing industrial wastewater, ecological river restoration and river ecosystem management by enhancing water quality, as well as microbial products primarily used for pollutant removal and water quality enhancement, through the Company’s operating subsidiary, Shandong Dingxin Ecology Environmental Co., Ltd. In addition, through its operating subsidiary Suncare (Shanghai) Health Technology Co., Ltd., the Company operates an AI-powered, community-based senior health and elderly care platform serving China’s aging population. For more information, please visit the Company’s website.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations regarding future events. Investors can identify these statements by words or phrases such as “plans,” “expects,” “intends,” “believes,” “will,” “may,” “could,” “potential,” and similar expressions. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.

Investor Relations Contact:

WFS Investor Relations Inc.
Connie Kang, Partner
Email: ckang@wfsir.com
Tel: +86 1381 185 7742

International Scientific Presentation Underscores Encouraging Clinical Outcomes and Additional Biological Potency Findings Supporting Cell-Free Regenerative Platform

PHOENIX, Oct. 20, 2026 (GLOBE NEWSWIRE) — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine technologies, today highlighted additional clinical and laboratory findings for Ultrasome™, its investigational cell-free regenerative medicine platform, following a presentation at the Annual Meeting of Experts in Cell and Gene Therapy held October 10, 2026, in Lima, Peru.

The study evaluated 30 patients with bilateral knee osteoarthritis over six months and found that 28 of 30 participants (93%) met study-defined response criteria. Importantly, the group’s average reported pain score declined by approximately 65% from baseline to six months. The 65% figure refers to the reduction in the group-average pain score – not the percentage of patients reporting improvement.

Clinical Results: 93% Response and Meaningful Average Symptom Improvement

• 93% patient response: 28 of 30 participants met the study-defined criteria for clinical improvement.
• 65% reduction in average pain score at six months post intervention.
• 52% reduction in average WOMAC score: Mean scores reflecting osteoarthritis-related pain, stiffness and physical limitations improved over six months.
• Improved quality of life: The group’s average knee-related quality-of-life score increased by approximately 35 points.
• Preliminary safety: No serious adverse events were reported during six months of follow-up.

Additional Scientific Findings Support Ultrasome™ Platform Development

Complementing the clinical observations, laboratory studies demonstrated significant reductions in biological markers associated with cartilage degradation and inflammatory signaling. Product characterization and functional potency testing also provided encouraging findings supporting further evaluation of manufacturing quality controls and product consistency.

The Company anticipates that the full scientific findings, including detailed potency analyses, statistical evaluations, tables and figures, will be included in a manuscript planned for peer-reviewed publication.

A Scalable Cell-Free Regenerative Medicine Opportunity

Ultrasome™ builds upon Creative Medical’s regenerative medicine technology platform associated with CELZ-201 (Olastrocel), using extracellular-vesicle-rich secretome material in an investigational cell-free therapeutic approach. The Company believes this strategy may offer potential future advantages in manufacturing, distribution and development across osteoarthritis and other degenerative conditions.

“These findings represent an encouraging milestone for Ultrasome,” said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings. “With 93% of patients meeting study-defined response criteria and an approximately 65% reduction in the group’s average pain score, we believe the results strengthen the rationale for further development. The additional potency findings reinforce our focus on a scalable, biologically active regenerative medicine platform with significant long-term opportunity.”

The 30-patient study was an open-label, single-arm pilot without a randomized or sham-controlled comparator.

About Ultrasome™

Ultrasome™ is Creative Medical’s investigational cell-free regenerative medicine platform utilizing extracellular-vesicle-rich secretome material. Ultrasome™ is not FDA-approved for knee osteoarthritis or other indications.

About Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a clinical-stage biotechnology company developing regenerative medicine technologies, including cell-based and cell-free approaches, targeting significant unmet medical needs. For more information, visit www.creativemedicaltechnology.com.

Forward-Looking Statements

This press release contains forward-looking statements concerning Ultrasome™, future research, clinical development, regulatory pathways, manufacturing, potential applications and commercialization opportunities. Actual results may differ materially due to risks including the possible failure to reproduce preliminary findings in controlled studies, regulatory decisions, manufacturing challenges, financing needs and other factors described in the Company’s SEC filings. The Company undertakes no obligation to update these statements except as required by law.

Investor & Media Contacts

Creative Medical Technology Holdings, Inc.
IR@CreativeMedicalTechnology.com
www.creativemedicaltechnology.com

Investor Relations / The Equity Group Inc.
Devin Sullivan
devin.sullivan@theequitygroup.com

Conor Rodriguez
conor.rodriguez@theequitygroup.com

The Company expects the new platform to generate orders from existing and new drone manufacturers

Rehovot, Israel, Oct. 20, 2026 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global leader in edge computing, artificial intelligence (“AI”), and video intelligence solutions for defense applications, today announced the launch of Uranus-Drones-V2, a compact video and AI processing platform designed for integration into unmanned aerial vehicles (“UAVs”).

Uranus-Drones-V2 supports up to four ultra high definition (UHD) camera inputs and eight camera inputs in total, with processing capabilities exceeding 30 tera operations per second (TOPS). The platform is designed to support a range of drone applications, including surveillance, tracking, and loitering munitions.

The platform connects directly to the drone’s autopilot and incorporates onboard inertial and environmental sensors. Combined with its video and AI processing capabilities, these features enable high-level autonomous flight functionality. Its small size, low weight, and low power consumption support integration into drones with demanding size, weight, and power requirements.

Building on its experience supplying video processing technology to the drone market, Maris-Tech believes Uranus-Drones-V2 will address the evolving requirements of drone manufacturers and expects the platform to generate orders from both existing and new customers.

Israel Bar, Chief Executive Officer of Maris-Tech, commented, “Uranus-Drones-V2 is the result of the Company’s deep understanding and extensive experience in the drone market, gained through thousands of operational deployments. It delivers impressive performance on a platform that is small, lightweight, and low power.”

About Maris-Tech Ltd.

Maris-Tech delivers AI-powered edge video solutions for mission-critical defense and security operations, enabling real-time situational awareness, intelligence gathering, and surveillance in bandwidth- and latency-constrained environments. Trusted by leading security organizations, Maris-Tech platforms are deployed across UAVs, UGVs, armored vehicles, and dismounted soldier systems, supporting missions that require ultra-low-latency video processing and onboard AI analytics. From intelligence collection in extreme conditions to AI-driven surveillance and terrain dominance, Maris-Tech masters the AI video pipeline at the edge through best-in-class SWaP-optimized, ruggedized computing solutions.

For more information, visit https://www.maris-tech.com/

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect” “may”, “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it discusses the anticipated advantages, benefits, performance and capabilities of its Uranus-Drones-V2 platform, including its ability to support various drone applications and advanced autonomous flight functionality, its belief that the platform will address the evolving requirements of drone manufacturers, and its expectation that the platform will generate orders from existing and new customers. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: its ability to successfully market its products and services, including in the United States; the acceptance of its products and services by customers; its continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; its ability to successfully develop new products and services; its success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; its ability to comply with applicable regulations; and the other risks and uncertainties described in the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on May 15, 2026, and its other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations:

Nir Bussy, CFO
Tel: +972-72-2424022
Nir@maris-tech.com

NORTH BETHESDA, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) — Xometry, Inc. (NASDAQ: XMTR), the global AI-native marketplace connecting buyers and suppliers of custom manufacturing, today announced it will report its third quarter 2026 financial results before the market opens on November 3, 2026.

Xometry will host its conference call and webcast to discuss the results at 8:30 a.m. ET (5:30 a.m. PT) on the same day. In addition to its press release announcing its third quarter 2026 financial results, Xometry will also release an earnings presentation, which will be available on its Investor Relations website.

Xometry, Inc. Q3 2026 Earnings Presentation and Conference Call

• Tuesday, November 3, 2026
• 8:30 a.m. ET / 5:30 a.m. PT
• Investors and participants can register in advance here.
• You may also visit the Xometry Investor Relations Homepage at investors.xometry.com to listen to a live webcast of the call.

The earnings presentation webcast will be archived within the Investor Relations section of Xometry’s website.

About Xometry
Xometry’s (NASDAQ: XMTR) AI-native marketplace, popular Thomasnet^® industrial sourcing platform and suite of cloud-based services are rapidly digitizing the manufacturing industry. Xometry provides manufacturers the critical resources they need to grow their businesses and streamlines the procurement process for buyers through real-time pricing and lead time data. Learn more at xometry.com or follow Xometry on LinkedIn.

Investor Contact
Shawn Milne
VP Investor Relations
240-335-8132
shawn.milne@xometry.com

Media Contact
Lauran Cacciatori
VP Communications
773-610-0806
lauran.cacciatori@xometry.com

TORONTO, Oct. 20, 2026 (GLOBE NEWSWIRE) — MAK Acquisition Corp. (TSX: MAK.U) (“MAK”) announced today that it has delivered a notice of termination to Uni Express Inc. (“UniUni”) the purchase agreement dated May 15, 2026 (the “Purchase Agreement”) among MAK, UniUni and Jun Wei (Peter) Lu, which governed the proposed reverse take-over transaction between MAK and UniUni that was intended to constitute MAK’s “qualifying acquisition” under Part X of the TSX Company Manual (the “Proposed Transaction”).

As previously announced on September 24, 2026, MAK delivered a notice of breach to UniUni regarding UniUni’s breach of its interim covenant to operate its business within specified parameters, including a defined maximum cumulative pre-tax loss. Under the Purchase Agreement, UniUni had 15 business days following receipt of the notice of breach to cure the breach, however the breach was incurable as UniUni exceeded its maximum cumulative pre-tax loss. That cure period expired on October 19, 2026 without the breach having been cured. As a result, MAK has exercised its right to terminate the Purchase Agreement, and the Proposed Transaction will not proceed. MAK has also advised UniUni that it reserves all of its rights.

MAK remains a special purpose acquisition corporation formed under the laws of the Cayman Islands for the purpose of effecting a qualifying acquisition of one or more businesses or assets. MAK will continue its search for niche-market businesses providing critical solutions, with strong revenue retention and diversified customer bases, with a view to completing a qualifying acquisition.

Withdrawal of Preliminary Prospectus

In connection with the Proposed Transaction, MAK filed a preliminary long form non-offering prospectus dated June 10, 2026 (the “Preliminary Prospectus”) with securities regulatory authorities in each of the provinces of Canada except Québec, for which a receipt was issued on June 11, 2026. As the Proposed Transaction will not proceed, MAK is withdrawing the Preliminary Prospectus and will not file a final prospectus. Investors should not rely on the Preliminary Prospectus, or on the information concerning UniUni or the Proposed Transaction contained in it or in MAK’s news releases dated May 15, 2026 and June 11, 2026.

About MAK Acquisition Corp.

MAK is a special purpose acquisition corporation focused on niche-market businesses providing critical solutions, with strong revenue retention and diversified customer bases. MAK is an exempted company formed under the laws of the Cayman Islands. MAK completed its initial public offering in October 2025 and its securities are listed on the Toronto Stock Exchange under the symbols “MAK.U” and “MAK.WT”. For more information, visit www.makacquisitioncorp.com.

Forward-Looking Information

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws, including with respect to the termination of the Purchase Agreement, MAK’s pursuit of a qualifying acquisition and MAK’s rights and remedies. This forward-looking information is identified by the use of terms and phrases such as “may”, “would”, “should”, “could”, “expect”, “intend”, “estimate”, “anticipate”, “plan”, “foresee”, “believe”, or “continue”, the negative of these terms and similar terminology, including references to assumptions, although not all forward-looking information contains these terms and phrases. Economic and geopolitical uncertainties, including regional conflicts and wars, including potential impacts of sanctions, may also heighten the impact of certain factors described herein. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances.

Forward-looking information is based on management’s beliefs and assumptions and on information currently available to management. Although the forward-looking information contained herein is based upon what we believe are reasonable assumptions, investors are cautioned against placing undue reliance on this information since actual results may vary from the forward-looking information.

Forward-looking information involves known and unknown risks and uncertainties, many of which are beyond our control, that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to, the risk that MAK may not identify or complete an alternative qualifying acquisition on suitable terms, or at all, within the permitted time, the risk of disputes or litigation arising from the termination of the Purchase Agreement, and the other risk factors described in detail under “Risk Factors” in MAK’s final long form prospectus dated October 22, 2025.

Consequently, all of the forward-looking information contained herein is qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments that we anticipate will be realized or, even if substantially realized, that they will have the expected consequences or effects on our business, financial condition or results of operations. Unless otherwise noted or the context otherwise indicates, the forward-looking information contained herein represents our expectations as of the date hereof or as of the date it is otherwise stated to be made, as applicable, and is subject to change after such date. However, we disclaim any intention or obligation or undertaking to update or amend such forward-looking information whether as a result of new information, future events or otherwise, except as may be required by applicable law.

For further information, please contact:

Investor Relations Contact:

Ross Marshall
Phone: 416.526.1563
Email: ross.marshall@loderockadvisors.com

SHANGHAI, Oct. 20, 2026 (GLOBE NEWSWIRE) — FREELANDER hosted FREELANDER Nightfall at the Hengli Hotel in Wuhu on 19 October as part of the 2026 Chery International User Summit. At the brand evening, the brand displayed the international five-seat version of FREELANDER 8 for the first time, announced its AI Voice Assistant, confirmed that FREELANDER 8 is expected to launch in the UAE in the first quarter of 2027 and signed partnership agreements with new partners in Bahrain and Oman.

The evening followed the first test drive of the international variant of FREELANDER 8, held earlier that day at Tuju Campground. Guests were welcomed by Mornine, an embodied AI humanoid robot from Chery International’s AiMOGA brand, before exploring FREELANDER 8 on display and joining the stage programme.

FREELANDER Nightfall – Group photo featuring speakers, group executives and dealer representatives

International Five-Seat Debut and British Design

Alongside the six-seat version, the international five-seat version of FREELANDER 8 made its first public appearance, giving customers a choice of two-row and three-row layouts.

Mr Phil Simmons, EVP of the FREELANDER Design Hub, who was part of the team that designed the original Freelander launched in 1997, shared the design story behind FREELANDER 8. He highlighted the Castle-Style Body Design, the Yacht-Style Waistline and the Iconic Triangle Window, whose shape holds the letters F and L.

“You can see the family look: simple surfaces, soft lines, a friendly face. FREELANDER 8 keeps that spirit — but it is bigger, more modern and more premium,” said Mr Simmons.

Mr Phil Simmons, EVP of the FREELANDER Design Hub, presents the design of FREELANDER 8 at FREELANDER Nightfall

AI Voice Assistant

Ms Lucia Mao, CEO of FREELANDER International, announced the AI Voice Assistant, powered by a large language model and tailored for FREELANDER. Designed to bring more natural conversations and a deeper understanding of the vehicle, it builds on the intelligent cockpit of FREELANDER 8, which is powered by the Qualcomm SA8295P Automotive-Grade Chip and features a 46.3-inch Mini LED far-side screen, with L2+ driver assistance as standard.

Ms Lucia Mao, CEO of FREELANDER International, introduces the AI Voice Assistant at FREELANDER Nightfall

Three-Phase Roll-out and UAE Launch Timing

FREELANDER also shared its three-phase international roll-out. Phase one begins in the UAE and expands across the Middle East and international left-hand drive markets. Phase two enters right-hand drive markets, prioritising Australia and New Zealand. Phase three enters continental Europe, followed by the United Kingdom and Ireland.

FREELANDER 8 is expected to launch in the UAE in the first quarter of 2027, when the brand will share further details on space, safety and service, along with specifications and pricing.

“For me, bringing FREELANDER to the world means more than entering new markets. It means earning the trust of our customers, every day. That takes a great product, strong local partners and service people can rely on,” said Ms Mao.

New Partners in Bahrain and Oman

The evening also featured a signing ceremony with two new partners in the Middle East. Mr Tim Zhang, General Manager of the Middle East Region, Chery International, signed partnership agreements on behalf of FREELANDER with EK Kanoo Group in Bahrain and Saud Bahwan Group in Oman, witnessed by Ms Mao. Mr Talal Fuad Ebrahim Kanoo, Managing Director of EK Kanoo Group, signed for the Bahrain partner. Mr Abdullah Mohammed Saud Bahwan, CEO of Saud Bahwan Group, signed for the Oman partner.

The agreements extend FREELANDER’s network in the region, where Al Tayer Motors and Premier Motors are its official dealer partners in the UAE.

Beyond the Legend

FREELANDER’s programme at the Summit continues with test drives on an obstacle course and a paved test course on 21 October. Together, the programme shows how FREELANDER 8 brings together premium heritage, intelligent technology and all-terrain capability. This combination reflects the brand slogan “Beyond the Legend” and its vision of building on its heritage through intelligent innovation and distinctive design.

About FREELANDER

FREELANDER is a British Premium Intelligent All-Terrain Brand, jointly developed by JLR and Chery Group. JLR owns the FREELANDER brand and has established a dedicated FREELANDER Design Hub to lead its design. Chery provides advanced intelligent technology and a top-tier global supply chain. The brand’s global foundation includes more than 5,000 employees, five strategic hubs and fully integrated capabilities spanning design, R&D, manufacturing and global operations.

Media contact
Daniel Bao
freelander.international@mychery.com
https://www.cheryinternational.com/

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/c0d39c41-2a6d-4c0b-8fcb-d1444275fcb5

https://www.globenewswire.com/NewsRoom/AttachmentNg/6f0ce3ec-587f-48f7-9f3a-1efd543af130

https://www.globenewswire.com/NewsRoom/AttachmentNg/cde36697-3937-4d20-894d-1f6437d05c7f

Integration delivers continuous sensitive data classification in Collibra’s Data Catalog, giving governance, privacy, and security teams added context without manual tagging

MIAMI, Oct. 20, 2026 (GLOBE NEWSWIRE) — Varonis Systems, Inc. (NASDAQ: VRNS), the data and AI security leader, today announced an integration that brings sensitive data context directly into the Collibra Enterprise AI Control Plane. Teams can see continuously synced Varonis sensitivity labels in the Collibra data catalog to instantly tell whether data is safe for AI.

Successful AI initiatives depend on trusted data that teams can find, understand, and use safely. Varonis identifies and classifies sensitive and regulated information across the data estate. Collibra tracks where data comes from and how people use it, so organizations can govern what powers their analytics and AI.

Together, Varonis and Collibra help organizations gain a clear and current view of what’s safe to use for analytics, data science, and agent development.

With the integration, teams can:

• Check sensitivity before using data for AI: Teams see sensitivity labels while evaluating information for training, analytics, and other projects.
• Flag regulated information: Collibra workflows highlight regulated data like personally identifiable information (PII), protected health information (PHI), and financial records.
• Work from one shared picture: Governance, privacy, and security teams now see the same view of what’s sensitive.

“Trustworthy AI starts with trustworthy data,” said Rob Sobers, CMO at Varonis. “With hundreds of connectors across SaaS applications, cloud platforms, and databases, Varonis gives Collibra customers deep visibility into data sensitivity so their teams can make smarter, faster decisions about which data to use for AI.”

The integration is available now for joint customers on the Collibra Marketplace.

To see it in action, request a demo at varonis.com/demo.

Additional Resources

• Read more on the Varonis blog.
• Schedule a personalized Varonis demo.
• Visit our blog, and join us on LinkedIn and YouTube.

About Varonis
Varonis (Nasdaq: VRNS) secures AI and the data that powers it. The Varonis platform gives organizations automated visibility and control over their critical data wherever it lives and helps ensure safe and trustworthy AI from code to runtime. Backed by 24x7x365 managed detection and response, Varonis gives thousands of organizations worldwide the confidence to adopt AI, reduce data exposure, and stop AI-powered threats.

Investor Relations Contact

Tim Perz
Varonis Systems, Inc.
646-640-2112
investors@varonis.com 

News Media Contact

Rachel Hunt
Varonis Systems, Inc.
877-292-8767 (ext. 1598)
pr@varonis.com 

First in a planned network of specialty pharmacy partnerships provides medication coordination and preferred pricing for OB/GYNs and their patients

ATLANTA, Oct. 20, 2026 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today an agreement with SandsRx Pharmacy, marking the first in a planned network of specialty pharmacy partnerships supporting the launch of FemaSeed and Femasys’ comprehensive fertility portfolio to OB/GYN practices. The partnership complements a portfolio spanning diagnostics for women and men, sperm preparation and in-office fertility treatment by providing specialized pharmacy support, coordinated medication access and preferred pricing. For patients undergoing FemaSeed treatment, fertility medications may be prescribed to support ovulation and improve the likelihood of pregnancy.

“FemaSeed is creating a new opportunity for OB/GYNs to provide first-line fertility treatment in their own practices, bringing care historically performed primarily by infertility specialists into a familiar setting,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys. “FemaSeed places sperm directly where conception occurs, and managing ovulation and treatment timing is essential to supporting pregnancy outcomes. Partnerships with specialty pharmacies such as SandsRx bring valuable medication expertise, education and coordination to practices introducing this treatment. These resources help support successful integration of FemaSeed and our broader fertility portfolio into OB/GYN care.”

“We are excited to expand our fertility pharmacy support to OB/GYN practices through Femasys’ FemaSeed treatment solution,” said Mike Sands, Co-Founder and Chief Executive Officer of SandsRx Pharmacy. “We have supported the fertility community through reproductive centers, and this partnership allows us to reach patients earlier in their fertility journey through their OB/GYN. By providing medication expertise, education and personalized support, we can help these practices integrate FemaSeed and guide patients through treatment with greater confidence.”

About FemaSeed Fertility Portfolio
The Femasys Fertility Portfolio is designed to support a more complete fertility care pathway, beginning with diagnostic evaluation for both women and men through FemVue, which uses ultrasound to assess fallopian tube patency, and SpermVue, an at-home male fertility screening option that can help identify potential barriers to conception earlier. FemaSeed Complete combines FemaSeed with FemSperm for in-office sperm handling, enabling practices to provide first-line fertility treatment without the need for referral to a specialist or outside laboratory. Together, the portfolio is designed to enable earlier fertility care that is more accessible and lower cost. Learn more at www.femaseed.com and www.femvue.com.

About Femasys Inc.
Femasys is a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide. The Company is focused on commercializing its fertility portfolio, led by FemaSeed^® Intratubal Insemination, together with complementary diagnostic and sperm preparation products, in the U.S. and key international markets. Femasys is also advancing FemBloc^®, its non-surgical, in-office permanent birth control solution, toward U.S. FDA approval through the ongoing FINALE pivotal trial (NCT05977751). FemBloc received regulatory approvals in Europe, the UK and New Zealand in 2025, supporting commercialization through strategic partnerships in select international markets. Femasys’ portfolio is supported by broad intellectual property protection and clinical data demonstrating favorable safety, encouraging effectiveness results, and high patient and practitioner satisfaction.
Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.

About SandsRx Pharmacy
Founded in 2013, SandsRx Pharmacy is a family-owned and operated specialty and compounding pharmacy serving patients and healthcare providers across the United States. Its fertility services include specialty and compounded medications, insurance verification, financial assistance programs, pharmacist consultations, virtual nurse support and coordinated medication delivery. Committed to personalized care, SandsRx works closely with patients and their healthcare teams to provide education and support throughout the fertility treatment journey. Learn more at www.sandsrx.com.

Forward-Looking Statements 
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

Contacts: 
IR@femasys.com
Media@femasys.com